Press release
Gout Pipeline: Advancing Innovation with 25+ Leading Companies Developing Cutting-Edge Therapies | DelveInsight
Gout Pipeline
DelveInsight's "Gout Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Gout market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Gout drugs, the Gout pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Gout Pipeline Report
• DelveInsight's Gout Pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline drugs for Gout treatment.
• The leading Gout companies include Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical, and others are evaluating their lead assets to improve the Gout treatment landscape.
• Key Gout pipeline therapies in various stages of development include ABP-745, SHR4640, SEL-212, LC350189, SAP-001, AC-201, Dapansutrile, URC-102, Bucillamine, HP501, AR882, DYV700, ABP-671, Anakinra, ALLN-346, TMX-049, Verinurad, RPH-104, D-0120, and others.
• In March 2025, XORTX Therapeutics Inc. (NASDAQ: XRTX) announced it will submit a Type B meeting package to the FDA, with expected communication by April 26, 2025, regarding its treatments for progressive kidney disease and gout.
• In January 2025, Scilex Holding Company amended its license agreement with Romeg Therapeutics, LLC, securing worldwide rights to commercialize Gloperba®, an FDA-approved treatment for painful gout flares in adults.
• In August 2024, the FDA approved an updated label for Gloperba, an oral liquid colchicine formulation, enabling precision dosing for acute gout flare prevention.
• Also in August 2024, Arthrosi Therapeutics, Inc. received Fast Track Designation from the FDA for AR882, a next-generation URAT1 inhibitor, for treating clinically visible tophi in gout patients.
Request a sample and discover the recent breakthroughs happening in the Gout pipeline landscape @ https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gout Overview
Gout is a type of inflammatory arthritis caused by the accumulation of urate crystals in the joints due to elevated uric acid levels in the blood. It leads to sudden and severe pain, redness, and swelling, most commonly affecting the big toe. Gout progresses through four stages: asymptomatic hyperuricemia (elevated uric acid without symptoms), acute gout (painful flare-ups), intercritical gout (symptom-free periods between attacks), and chronic gout (persistent joint damage and tophi formation). Risk factors include genetics, obesity, high-purine diets (red meat, seafood, sugary drinks), alcohol consumption, and medical conditions like diabetes, hypertension, and kidney disease. Although men are more prone to gout, the risk increases in women after menopause due to hormonal changes.
Management focuses on relieving acute attacks and preventing future flare-ups. NSAIDs, colchicine, and corticosteroids help reduce pain and inflammation during attacks, while medications like allopurinol and febuxostat lower uric acid levels to prevent recurrence. Lifestyle changes, including a healthy diet, weight management, reduced alcohol intake, and proper hydration, play a crucial role in controlling gout. If left untreated, gout can progress to chronic stages, causing joint damage, persistent pain, and kidney stones. However, with timely treatment and lifestyle adjustments, gout can be effectively managed, minimizing its impact on daily life.
Find out more about Gout medication @ https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gout Treatment Analysis: Drug Profile
LC350189: LG Chem
Tigulixostat (LC350189) is a novel xanthine oxidase inhibitor designed to reduce uric acid levels by inhibiting xanthine oxidase activity in purine metabolism. Unlike traditional xanthine oxidase inhibitors such as allopurinol, which is a purine analog, tigulixostat has a distinct molecular structure. It is being developed as a first-line treatment in the U.S. and has demonstrated strong efficacy in lowering serum uric acid (sUA) levels along with a favorable safety profile in Phase II clinical trials. The drug is currently in Phase III development for the treatment of gout.
SAP-001: Shanton Pharma
SAP-001 is an investigational therapy developed by Shanton Pharma for refractory and tophaceous gout, a severe form of the disease that does not respond well to standard treatments. The drug acts as a urate transporter 1 (URAT1) inhibitor, effectively lowering uric acid levels in patients who have shown inadequate response to conventional therapies like allopurinol and febuxostat. Currently, SAP-001 is in Phase II clinical development for the treatment of gout.
Key Gout Therapies and Companies
• LC350189: LG Chem
• SAP-001: Shanton Pharma
• D-0120: InventisBio
• ABP-745: Jiangsu Atom Bioscience and Pharmaceutical
• SEL-212: Cartesian Therapeutics/Swedish Orphan Biovitrum (Sobi)
• AR882: Arthrosi Therapeutics
• SAP-001: Shanton Pharma
• DYV700 : Dyve Biosciences
Learn more about the novel and emerging Gout pipeline therapies @ https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Gout Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide
Scope of the Gout Pipeline Report
• Coverage: Global
• Key Gout Companies: Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical, and others.
• Key Gout Pipeline Therapies: ABP-745, SHR4640, SEL-212, LC350189, SAP-001, AC-201, Dapansutrile, URC-102, Bucillamine, HP501, AR882, DYV700, ABP-671, Anakinra, ALLN-346, TMX-049, Verinurad, RPH-104, D-0120, and others.
Dive deep into rich insights for drugs used for Gout treatment; visit @ https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Gout Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Gout Pipeline Therapeutics
6. Gout Pipeline: Late-Stage Products (Phase III)
7. Gout Pipeline: Late-Stage Products (Phase III)
8. Gout Pipeline: Mid-Stage Products (Phase II)
9. Gout Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gout Pipeline: Advancing Innovation with 25+ Leading Companies Developing Cutting-Edge Therapies | DelveInsight here
News-ID: 3954229 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Gout
Chronic Gout Market Trends, Therapeutics, and Growth Opportunities
Chronic gout is a progressive form of arthritis characterized by elevated uric acid levels, leading to severe joint pain, inflammation, and long-term joint damage. This condition affects millions worldwide, often resulting in impaired mobility and reduced quality of life. With rising prevalence due to lifestyle changes, aging populations, and dietary habits, the Chronic Gout market is witnessing a surge in demand for advanced therapeutics, early diagnostics, and patient management solutions.
Download…
Chronic Gout Market Massive Growth opportunity Ahead
Introduction
Chronic gout is a form of arthritis characterized by recurrent attacks of severe pain, swelling, and inflammation in the joints, often due to the accumulation of uric acid crystals. This condition typically affects the big toe but can also impact other joints, including the knees, elbows, and wrists. Uric acid, a by-product of purine metabolism, accumulates in the body due to overproduction or underexcretion by the kidneys, leading to hyperuricemia…
Gout Market Innovations in Pain Management and Treatment
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Gout Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many…
Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory …
Report Summary
The global gout therapeutics market was valued at USD 2.78 Billion in 2021 and is expected to grow at a CAGR of 13.7% during the forecast period 2023-2032.
Gout Therapeutics Market Introduction
The deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues results in gout, an inflammatory arthritic disease. Gout is a typical type of painful inflammatory arthritis. One joint is typically affected at a time (often…
Global Gout Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Gout Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Gout Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/371311/gout-drugs
Market…
Gout Therapeutics Market Emerging Trends And Forecast By 2025
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Patients with multiple episodes of severe gout attacks every year or with…
